证券日报网讯12月23日，太极集团（600129）在互动平台回答投资者提问时表示，公司下属子公司太极 集团海南医药研究有限公司、海南太极海洋药业有限公司及海南太极医疗养生有限公司注册地均为海南 省，相关情况敬请关注公司发布的公告。 ...

Group 1 - Ningbo Huaxiang's subsidiary signed a contract for the production of robot joints, which will enhance its competitive advantage in smart robot components [1] - The contract will not significantly impact the company's current financial performance, but will positively affect future results starting from January 2026 [1] Group 2 - Jiufeng Energy's special fuel and gas supply project for the Hainan commercial space launch site is nearing completion, with products already validated through multiple rocket launches [2] - The company is advancing its Phase II expansion plan with an estimated total investment of approximately 300 million yuan [2] Group 3 - Zhenyu Technology plans to invest at least 1 billion yuan in projects related to core components for humanoid robots and other advanced technologies [3] - The company has signed strategic cooperation agreements for these investments, indicating a strong commitment to expanding its technological capabilities [3] Group 4 - Haibo Shichuang's subsidiary plans to invest 2 billion yuan in a smart green energy storage factory project, aimed at enhancing R&D and manufacturing capabilities [2] - The project is expected to positively impact the company's financial status and long-term sustainability [2] Group 5 - Various companies are involved in significant equity transfers and acquisitions, including ST Jinglan's acquisition of a 51% stake in a South African company and Jianlong Micro-Nano's 200 million yuan acquisition of a 40% stake in Hanxing Energy [5] - Other notable transactions include China Power Construction signing a contract for a Turkish gas booster station project worth approximately 6.626 billion yuan [5]

Core Viewpoint - Taiji Group announced the public transfer of a 40% stake in Chongqing Aida Taiji Spring Water Co., Ltd. held by its wholly-owned subsidiary, Fuling Pharmaceutical Factory, through a public listing method [1] Group 1 - The company is planning to divest its stake in Chongqing Aida Taiji Spring Water Co., Ltd. [1] - The stake being transferred is 40%, indicating a significant ownership interest in the water company [1] - The transfer will be conducted through a public listing, suggesting a transparent process for potential buyers [1]

Group 1 - Shareholder of Okoyi plans to reduce holdings by up to 1.89% of the company's shares, amounting to a maximum of 3 million shares due to personal funding needs [1] - Tianchuang Fashion is planning a change in control, leading to continued suspension of its stock trading, expected to last no more than 3 trading days [2] - China Electric Power Construction Company reported a new contract amount of 10,317.55 billion yuan for the first 11 months of 2025, a year-on-year decrease of 1.65% [3] Group 2 - Pilin Bio's wholly-owned subsidiary received approval for a clinical trial of a drug, indicating progress in its product development [4] - Yihong Medical obtained two medical device registration certificates for diagnostic kits, enhancing its product portfolio [5] - Aohong Electronics plans to use up to 450 million yuan of idle fundraising for cash management, targeting safe and liquid financial products [6] Group 3 - China Electric Power Construction signed a contract worth approximately 6.626 billion yuan for a natural gas booster station project in Turkey, with a construction period of about 55 months [7] - Baosheng Co. won a bid for a power cable project in Singapore, valued at around 1.2 billion yuan, marking the largest overseas order in its history [8] - *ST Xinyan's stock will resume trading on December 24, 2025, following a capital increase plan that will raise its total share capital to 3.29 billion shares [9] Group 4 - Ningbo Construction's subsidiary signed a construction contract worth 428 million yuan for an engineering project with a duration of 990 days [11] - Lianhuan Pharmaceutical's subsidiary received approval for a drug that passed the consistency evaluation for generic drugs, enhancing its market competitiveness [12] - Zhongjie Automotive received a project designation for a new electric air conditioning compressor, with expected sales of approximately 29.86 million USD over its lifecycle [13] Group 5 - Biopharmaceuticals' major shareholder plans to increase holdings by 50 million to 100 million yuan, indicating confidence in the company's future [14] - Haizheng Pharmaceutical's subsidiary received approval for a veterinary drug product, expanding its product offerings in the animal health sector [15] - *ST Songfa's subsidiary signed contracts for the construction of 8 vessels, with a total contract value between 200 million to 400 million USD [16] Group 6 - Shandong Pharmaceutical Glass announced the resignation of its chairman due to age reasons, indicating a potential leadership transition [17] - Xinno Wei's subsidiary received approval for a clinical trial of a monoclonal antibody drug, indicating advancements in its drug development pipeline [18] - Ningbo Huaxiang's subsidiary secured an order for robot joints, expected to positively impact future business performance [19][20] Group 7 - China Resources Double Crane's subsidiary received approval for a clinical trial of a drug aimed at treating a genetic eye disease, reflecting ongoing R&D efforts [21] - Huaxin Technology's shareholders set a transfer price of 56.69 yuan per share for a block of shares, indicating active shareholder engagement [22] - Xinhua Net announced the resignation of its president due to job relocation, suggesting potential changes in management [23] Group 8 - Taiji Group plans to transfer a 40% stake in a subsidiary to focus on its core pharmaceutical business, enhancing operational efficiency [24] - Huaxin Construction's shareholder plans to increase holdings by 200 million to 400 million yuan, reflecting confidence in the company's prospects [25] - Dongjie Intelligent is planning to issue shares and cash for asset acquisition, with stock trading suspended until further notice [26] Group 9 - Wanrun New Energy was designated as a delivery warehouse for lithium carbonate futures, indicating its strategic position in the market [27] - Prolo Pharmaceutical's subsidiary received a drug registration certificate for an influenza treatment, expanding its product range [28] - Saiwu Technology invested 5 million yuan in a private equity fund focused on smart vehicles and energy innovation, indicating strategic investment in growth sectors [29] Group 10 - Bohui Innovation's subsidiary received approval for a clinical trial of an immunoglobulin drug, indicating progress in its product development [30] - Bohui Innovation's subsidiary also received a drug registration certificate for a coagulation factor product, enhancing its therapeutic offerings [31] - Hanghua Co. plans to allocate 146 million yuan of surplus fundraising for a new green printing materials project, reflecting a commitment to sustainability [32] Group 11 - Nova Star Cloud obtained a loan commitment letter from a bank for a share repurchase plan, indicating financial support for its capital management strategy [33] - Jimin Health established a joint venture for technology innovation, indicating a strategic move to enhance its technological capabilities [34] - Huili Pharmaceutical received a drug registration certificate for a medication used in treating digestive ulcers, expanding its product portfolio [35]

本次交易不构成《上市公司重大资产重组管理办法》规定的重大 资产重组。本次交易事项已经公司第十届董事会第三十四次会议审议 通过。 根据《上海证券交易所股票上市规则》，本次交易在董事会审批 权限范围内，无需提交公司股东大会审议。 重庆太极实业（集团）股份有限公司（以下简称：公司）全资子 公司太极集团重庆涪陵制药厂有限公司（以下简称：涪陵药厂）持有 重庆阿依达太极泉水股份有限公司(以下简称:阿依达公司)40%的股 份，该公司拟通过挂牌转让方式对外公开转让上述股份。 本次交易将通过公开挂牌方式转让，交易对方存在不确定性，尚 不确定是否构成关联交易。 证券代码：600129 证券简称：太极集团 公告编号：2025-091 重庆太极实业（集团）股份有限公司 关于全资子公司拟公开挂牌转让 参股公司股权的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 重要内容提示： 风险提示：本次交易将通过公开挂牌的方式转让，交易能否达成 及最终成交价格均存在不确定性。公司将密切关注本次交易的进展情 况，严格按照《上海证券交易所股票上市规则》等法律法 ...

Group 1 - The core point of the article is that Taiji Group is focusing on its main business by cleaning up its non-core assets, specifically planning to transfer 40% of its subsidiary's shares in Aida Company for a starting price of 10.8 million yuan [1] - Taiji Group's revenue composition for the year 2024 is as follows: industrial sector accounts for 56.82%, commercial sector for 54.42%, traditional Chinese medicine resources for 8.5%, health and international business for 3.72%, and other businesses for 1.22% [1] - As of the report, Taiji Group has a market capitalization of 10 billion yuan [1]

格隆汇12月23日丨太极集团(600129.SH)公布，为聚焦主业，加大"两资两非"企业清理，提升管理效 能，公司全资子公司涪陵药厂拟将持有阿依达公司40%的股份通过挂牌转让方式对外公开出让，本次挂 牌转让价格以评估值10.8万元为依据，首次公开挂牌转让价格为10.8万元，最终交易金额以实际成交价 格为准。 ...

Group 1 - The core point of the article is that Taiji Group's wholly-owned subsidiary, Fuling Pharmaceutical Factory, plans to publicly transfer its 40% stake in Aida Company to focus on its main business, with an initial listing price of 108,000 yuan [1] - The transaction has been approved by the board of directors and does not require a shareholders' meeting for further approval, indicating a streamlined decision-making process [1] - Aida Company reported revenue of 11.51 million yuan and a net loss of 16.78 million yuan from January to August 2025, with a net asset value of -28.96 million yuan as of August 31, 2025, and an assessed net asset value of 27,000 yuan [1] Group 2 - The final price and the counterparties involved in the transaction remain uncertain, highlighting potential challenges in the transfer process [1] - The company will provide timely updates on the progress of the transaction, indicating a commitment to transparency [1]

智通财经APP讯，太极集团(600129.SH)发布公告，为聚焦主业，加大"两资两非"企业清理，提升管理效 能，公司全资子公司涪陵药厂拟将持有阿依达公司40%的股份通过挂牌转让方式对外公开出让，本次挂 牌转让价格以评估值10.8万元为依据，首次公开挂牌转让价格为10.8万元，最终交易金额以实际成交价 格为准。 ...

人民财讯12月23日电，太极集团（600129）12月23日公告，公司全资子公司太极集团重庆涪陵制药厂有 限公司持有参股公司重庆阿依达太极泉水股份有限公司(简称"阿依达")40%的股份，该公司拟通过挂牌 转让方式对外公开转让上述股份，首次公开挂牌转让价格为10.8万元。此次转让有利于公司聚焦医药主 业，加大"两资两非"企业清理，提升管理效能。 ...